NCT06435507已完成1 期
Phase I Clinical Trial to Evaluate the Safety, Tolerability, and Pharmacokinetics of Single Doses of IM-250 in Healthy Volunteers
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 18
- 试验地点
- 1
- 主要终点
- Occurrence (number) of dose-limiting toxicities (DLT)
研究概览
简要总结
This is a first-in-human, phase I, open-label, monocenter, single dose-escalation study with 4 cohorts. The total trial duration for each participant will be not more than 98 d from screening to the end of the follow-up.
Twenty-four participants are planned to be enrolled in the trial. Each cohort may be expanded by up to 6 additional volunteers, resulting in a maximum of 48 participants possibly enrolled in the trial.
Ninety-six volunteers may need to be screened to include 48 volunteers.
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Sequential
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 50 Years（Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •Signed Informed Consent Form (ICF),
- •Age 18-50 y inclusive at the time of consent,
- •An understanding, ability, and willingness to fully comply with study interventions and restrictions,
- •Males who are willing to use a condom for contraception during the treatment and for 60 d after IMP administration, or who are convincingly sexually abstinent, or who are refraining from heterosexual intercourse; females who are willing to use a highly effective method for contraception during the treatment and for 90 d after IMP administration, or who are convincingly sexually abstinent, or who are refraining from heterosexual intercourse, or women not of child-bearing potential (WNOCBP).
- •Satisfactory medical assessment without clinically significant or relevant abnormalities as determined by medical history, physical examination (PE), clinical (vital signs including normal heart rate [50-90 bpm]), laboratory (hematology, biochemistry, urinalysis), and electrocardiographic (ECG) evaluation (corrected QTc interval within normal range). First degree AV blocks may be acceptable, if the pulse rate complies with the inclusion criteria.
- •Ability to provide written, personally signed and dated informed consent to participate in the study, in accordance with the International Conference on Harmonisation (ICH) Good Clinical Practice (GCP) Guideline E6 and applicable regulations, before completing any study-related interventions.
排除标准
- •Current or relevant history of physical or psychiatric illness, any medical disorder that may require treatment or make the participant unlikely to fully complete the study, or any condition that presents undue risk from the IMP or study interventions.
- •Any intake of substances (prescription medication, over-the-counter medicine, or herbal preparations with active ingredients) known to inhibit drug-metabolizing enzymes or transport enzymes within a period of less than 5 times the respective elimination t1/2 with regard to the expected date of IMP administration (except iodine, hormone replacement therapy, hormonal contraception, and levothyroxine).
- •Any intake of substances (prescription medication, over-the-counter medicine, or herbal preparations with active ingredients) known to induce drug-metabolizing enzymes or transport enzymes within a period of 14 d with regard to the expected date of IMP administration.
- •A positive result in testing for illegal drugs at screening and enrollment.
- •Male participants who consume more than 21 units of alcohol per week or 3 units per day. Female participants who consume more than 14 units of alcohol per week or 2 units per day.
- •Consumption of alcohol within 24 h prior to Day 1 and until End of Study (EOS).
- •Clinically relevant abnormalities regarding ECG conduction (AV block), hematocrit, hemoglobin (Hb), platelets, or leucocytes. A Hb value > 12 g / dl (males) or > 11 g / dl (females) is acceptable.
- •Abnormal renal function as defined by estimated creatinine clearance: < 90 ml / min (Cockcroft-Gault equation).
- •Alanine aminotransferase (ALT) > ULN x 1.1; aspartate aminotransferase (AST) > ULN x 1.
- •Thyroid-stimulating hormone (TSH) not within normal limits. If thyroid hormones are supplemented, reduced TSH values are acceptable, if free thyroxine (T4) and free triiodothyronine (T3), are within the normal range.
- •Total bilirubin > upper limit of normal (ULN) x 1.2; In case of suspected Gilbert´s disease: total bilirubin ≤ ULN x 3 is acceptable.
- •Any history of severe allergic or anaphylactic reactions to drugs or food or any other clinically significant allergies.
- •Known allergy / hypersensitivity to additives used in the IMP.
- •Use of another IMP within 30 d prior to receiving the dose of IMP or active enrolment in another drug or vaccine clinical trial.
- •A positive human antibody screen for immunodeficiency virus (HIV), or chronic hepatitis C virus (HCV), or a positive hepatitis B antigen (HBsAg) test.
- •History of immunization within 14 d prior to expected dosing, including SARS-CoV-2 vaccinations, and / or plans to get vaccinated during the observation time
- •Pregnancy or breast feeding
- •Prior exposure in this trial.
研究组 & 干预措施
Cohort 1
Experimental
6 participants
干预措施: IM-250 (50 mg) (Drug)
Cohort 2
Experimental
6 participants
干预措施: IM-250 (100 mg) (Drug)
Cohort 3
Experimental
6 participants
干预措施: IM-250 (200 mg) (Drug)
Cohort 4
Experimental
6 participants
干预措施: IM-250 (400 mg) (Drug)
结局指标
主要结局
Occurrence (number) of dose-limiting toxicities (DLT)
时间窗: within 28 days after exposure
* Serious adverse reaction (i.e., a serious adverse event (SAE) considered at least possibly related to IMP administration) * Severe (CTCAE grade III) non-serious adverse reactions (i.e., severe non-serious adverse event (AE) considered as, at least, possibly related to IMP administration) lasting more than 72 h
次要结局
- PK: The area under the plasma concentration-time curve extrapolated to infinity (AUC∞)(56 days)
- PK: Maximum plasma concentration (Cmax)(8 days)
- PK: Concentration at 24 h (C24h), 5 d (C5d), and 8 d (C8d)(24 hours, 5 days and 8 days)
研究者
研究点 (1)
Loading locations...
相似试验
招募中
早期 1 期
To Evaluate the Safety and Efficacy of Human CD19 Targeted DASH CAR-T Cells Injection for Subjects With R/R B-ALLB-cell Acute Lymphoblastic LeukemiaNCT05651191Hrain Biotechnology Co., Ltd.9
Unknown
1 期
A Phase I Clinical Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Anti-PD-1 Antibody (HLX10) in Combination With Avastin Biosimilar (HLX04) in Patients With Advanced Solid TumorsSolid TumorNCT03757936Shanghai Henlius Biotech30
进行中（未招募）
早期 1 期
To Evaluate the Safety and Efficacy of Human Derived Anti-BCMA CAR-T Injection for Subjects with R/R MMMultiple MyelomaNCT05302648Hrain Biotechnology Co., Ltd.18
招募中
早期 1 期
To Evaluate the Safety and Efficacy of Human BCMA Targeted CAR-NK Cells Injection for Subjects With R/R MM or PCLPlasma Cell LeukemiaMultiple MyelomaNCT06045091Hrain Biotechnology Co., Ltd.18
招募中
早期 1 期
Safety and Efficacy Study of NGGT003 in Hemophilia A PatientsHemophilia ANCT06238908Institute of Hematology & Blood Diseases Hospital, China6